title: Prevalence of mild fasting hyperhomocysteinemia in renal transplant versus coronary artery disease patients after fortification of cereal grain flour with folic acid.
abstract: Cereal grain flour products fortified with 140 microg folic acid per 100 g flour became widely available in southeast New England by July 1997. We hypothesized that improved folate status secondary to this fortification policy would have a much more limited impact on the prevalence of mild fasting hyperhomocysteinemia in renal transplant versus coronary artery disease patients. Between October 1997 and October 1998, fasting plasma total homocysteine (tHcy), folate and vitamin B12 levels were determined in a total of 86 renal transplant patients with stable allograft function, and 175 coronary artery disease patients whose serum creatinine was (1.4 mg/dl). All subjects lived in the Providence, RI, metropolitan area, and were either non-users of any supplements containing folic acid, vitamins B6 or B12, or had refrained from using such supplements for > or = 6 weeks. Geometric mean fasting tHcy levels were 88.0% higher (15.6 vs. 8.3 micromol/l; P < 0.001), and the prevalence of fasting tHcy levels > or = 12 microM (69.8% vs. 10.9%, P < 0.001) was markedly increased in the renal transplant patients, despite a much younger mean age and a relative preponderance of women. In the era of folic acid fortified flour, hyperhomocysteinemia is much more common in stable renal transplant versus coronary artery disease patients. As a result, renal transplant patients are a preferable high risk target population for controlled trials evaluating the tenable hypothesis that lowering total homocysteine levels will reduce cardiovascular disease outcomes.
authors.affiliation: Division of General Internal Medicine, Memorial Hospital of Rhode Island, Pawtucket 02860, USA. abostom@loa.com
authors.forename: A G
authors.initials: AG
authors.lastname: Bostom
authors.forename: R Y
authors.initials: RY
authors.lastname: Gohh
authors.forename: G
authors.initials: G
authors.lastname: Liaugaudas
authors.forename: A J
authors.initials: AJ
authors.lastname: Beaulieu
authors.forename: H
authors.initials: H
authors.lastname: Han
authors.forename: P F
authors.initials: PF
authors.lastname: Jacques
authors.forename: L
authors.initials: L
authors.lastname: Dworkin
authors.forename: I H
authors.initials: IH
authors.lastname: Rosenberg
authors.forename: J
authors.initials: J
authors.lastname: Selhub
mesh_terms: D003327:Coronary Disease / Q000097:blood*; D005215:Fasting; D005260:Female; D005433:Flour; D005492:Folic Acid / Q000008:administration & dosage* / Q000097:blood; D005527:Food, Fortified; D006710:Homocysteine / Q000097:blood; D006801:Humans; D020138:Hyperhomocysteinemia / Q000097:blood* / Q000209:etiology / Q000628:therapy; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D014805:Vitamin B 12 / Q000097:blood
chemical_list: D006710:Homocysteine; D005492:Folic Acid; D014805:Vitamin B 12